Biogen (MEX:BIIB) Other Gross PPE : MXN113,147 Mil (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Biogen Other Gross PPE?

Biogen's Other Gross PPE for the quarter that ended in Jun. 2024 was MXN113,147 Mil.

Biogen's quarterly Other Gross PPE increased from Dec. 2023 (MXN9,433 Mil) to Mar. 2024 (MXN102,425 Mil) and increased from Mar. 2024 (MXN102,425 Mil) to Jun. 2024 (MXN113,147 Mil).

Biogen's annual Other Gross PPE declined from Dec. 2021 (MXN10,183 Mil) to Dec. 2022 (MXN9,974 Mil) and declined from Dec. 2022 (MXN9,974 Mil) to Dec. 2023 (MXN9,433 Mil).

Biogen Other Gross PPE Historical Data

The historical data trend for Biogen's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Other Gross PPE Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

9,929.79

10,699.91

10,183.15

9,974.15

9,432.59

Biogen Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Other Gross PPE	Get a 7-Day Free Trial															102,105.64	106,345.85	9,432.59	102,425.45	113,146.79

Biogen Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Biogen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

BIIB:USA 1BIIB:Italy 0R1B:UK IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.